Rhinoplasty. 00
Conditions
Interventions
Intervention 1: Drug is administered with dose of 1000 mg (two 500 mg tablets) orally with about 20 cc of water are given to the patient's study 2 hours before surgery. Intervention 2: The second
Treatment - Drugs
Drug is administered with dose of 1000 mg (two 500 mg tablets) orally with about 20 cc of water are given to the patient's study 2 hours before surgery.
The second group or control group received placebo with about 20 cc of water 2 hours before surgery.
Sponsors
Vice-Chancellery of Research and Technology, Shiraz University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria included: The patients with systemic disease and no history of drug use, and willingness to cooperate in this study are enrolled? Exclusion criteria included known allergy to the study drug, hepatic and renal dysfunction and lack of signed informed consent will be excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of intraoperative bleeding. Timepoint: End of surgery. Method of measurement: Weight of the Gauze in the operating room for surgery with digital scale.;Blood pressure and heart rate values. Timepoint: Preoperative, intraoperative and postoperative. Method of measurement: Vital signs monitoring device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of postoperative oral tranexamic acid. Timepoint: Postoperative in recovery room. Method of measurement: The nurse reported in the recovery.;Agitation and postoperative shivering. Timepoint: Recovery room. Method of measurement: The nurse reported in the recovery. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid Reza Eftekharian
Shiraz University Of Medical Sciences
Outcome results
None listed